Seraxis gathers $40m Series C
Seraxis, a developer of cell replacement therapy for insulin-dependent diabetes, has secured $40 million in Series C financing.
Seraxis, a developer of cell replacement therapy for insulin-dependent diabetes, has secured $40 million in Series C financing.
Copyright PEI Media
Not for publication, email or dissemination
